FGP
BCRX icon

Freestone Grove Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Freestone Grove Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,735
Closed -$111K – 673
2025
Q1 		$111K Sell
14,735
-15,578
-51% -$126K ﹤0.01% 557
2024
Q4 		$228K Buy
+30,313
New +$230K ﹤0.01% 516

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Freestone Grove Partners's BCRX Position: Q2 2025 in Review

Freestone Grove Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 14,735 shares — an estimated $111K sold.

Freestone Grove Partners first reported a position in BCRX in Q4 2024 and held it in 2 quarters. The position peaked at $228K in Q4 2024. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

  • Freestone Grove Partners reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 14,735 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $111K.
  • Freestone Grove Partners first reported a position in BioCryst Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Freestone Grove Partners's BioCryst Pharmaceuticals position peaked at $228K in Q4 2024.
  • 294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Freestone Grove Partners's 13F filing for Q2 2025, filed 14 Aug 2025.